| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Research and development | 48,665 | 41,484 | 29,416* | |
| General and administrative | 26,412 | 17,736 | 12,161* | |
| Total operating expenses | 75,077 | 59,220 | 41,577 | |
| Loss from operations | -75,077 | -59,220 | -41,577* | |
| Interest income | 3,587 | 3,457 | 2,740* | |
| Interest expense | 1,233 | 1,245 | 1,371* | |
| Foreign exchange loss, net | -32 | -44 | -33* | |
| Change in fair value of 2022 usd financing warrants | 86,231 | 20,046 | 5,708* | |
| Gain on extinguishment of contribution payable | - | - | 0* | |
| Total other income/(expense) | -83,909 | -17,878 | -4,371* | |
| Net loss | -158,986 | -77,098 | -45,948* | |
| Unrealized gain/(loss) on investments | -406 | -262 | 83* | |
| Loss on foreign currency translation | -1 | 1 | -16* | |
| Comprehensive loss | -159,393 | -77,359 | -45,882 | |
| Basic EPS | -1.44 | -0.71 | -0.514 | |
| Diluted EPS | -1.44 | -0.71 | -0.514 | |
| Basic Average Shares | 110,684,720 | 108,790,941 | 89,327,608 | |
| Diluted Average Shares | 110,684,720 | 108,790,941 | 89,327,608 | |
Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. (DFTX)